Replication-attenuated r3LCMV vectors potentiate tumor control via IFN-I
Viral vectors are being used for the treatment of cancer. Yet their efficacy varies among tumors and their use poses challenges in immunosuppressed patients, underscoring the need for alternatives. We report striking antitumoral effects by a nonlytic viral vector based on attenuated lymphocytic choriomeningitis virus (r3LCMV). We show in multiple tumor models that injection of tumor-bearing mice with this novel vector results in improved tumor control and survival. Importantly, r3LCMV also improved tumor control in immunodeficient Rag1-/- mice. Single cell RNA-Seq analyses, antibody blockade experiments, and KO models revealed a critical role for host IFN-I in the antitumoral efficacy of r3LCMV vectors. Collectively, these data demonstrate potent antitumoral effects by a replication-attenuated LCMV vector and unveil mechanisms underlying its antitumoral efficacy. Overall design: Single-cell RNA-Sequencing of a tumor sample pooled from 5 mice challenged with tumor cells and then treated with r3LCMV and a tumor sample pooled from 5 different mice challenged with tumor cells and then treated with PBS. Each of the two tumor samples was enriched for CD45+ cells and then sequenced.